Skip to content
Screener

CG Oncology CGON Q4 2025 Annual earnings

Reported February 27, 2026 · Before market open

Revenue$2.3MBeat by $1.8M
EPS-$0.51Beat by $0.10
Revenue estimate$450.5K
EPS estimate-$0.61

Next report

Nov 13, 2026 (in 2 months)
Revenue estimate$547.7K
EPS estimate-$0.86

Financials

Q4 2025

Income statement

See full
Revenue$2.3M+409%
Operating income-$48.7M-28.0%
Net income-$41.3M-29.9%
EPS (diluted)-$0.51-6.3%

Balance sheet

See full
Cash & equivalents$32.5M-87.4%
Total debt$7.0M+2,850%
Total equity$752.6M+2.6%
Total assets$791.6M+4.9%

Cash flow

See full
Operating cash flow-$36.2M-75.3%
CapEx$7.0K-96.7%
Free cash flow-$36.2M-73.6%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$3.35B+53.4%
Enterprise value$3.32B+72.5%
P/S829×-1,088×

Profitability

See full
Operating margin-4,722.1%-1,638pp
Net margin-3,985%-1,300pp
FCF margin-3,279.2%-1,132pp

Returns & leverage

See full
Return on equity-21.7%—
Debt / equity0×0.0×
Current ratio24.6×-10.7×

Segments

By product

See full
Commercial And Development Revenue$1.7M—
License And Collaboration Revenue$596.0K+30.7%

FAQ

When did CG Oncology report Q4 2025 earnings?
CG Oncology (CGON) reported Q4 2025 earnings on February 27, 2026 before market open.
What were CG Oncology's Q4 2025 revenue and EPS?
CG Oncology reported revenue of $2.3M and eps of $-0.51 for Q4 2025.
Did CG Oncology beat estimates in Q4 2025?
Revenue beat the consensus estimate of $450.5K by $1.8M. EPS beat the consensus estimate of $-0.61 by $0.10.
How did CG Oncology's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 404.4% from $456.0K a year earlier and eps declined 6.3% from $-0.48.
Where can I find CG Oncology's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-079452) and the 10-K periodic report (0001193125-26-079498) directly on SEC EDGAR. The filing index links above go to sec.gov.